Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with more weight or obesity than only the use of tirzepatide treatment. Endo 2025Annual meeting of Endocrine Society at San Francisco, California.

Research Fellow, for the division of endocrinology at the Mayo Clinic in Jacksonville, Fla, said, “These figures are the first to show the combined use of tirzepetides and menopause hormone therapy, which increase the effectiveness of treatment in postmenopausal women.”

“Previous studies of the drug achieved similar results. Getting these results with another obesity can indicate a comprehensive efficacy tendency to add these two sections of drugs.”

Hormonal changes related to menopause often increase Abdominal fatSubjected Muscle And changed energy expenditureWho increases weight and risks to develop millions of women Heart disease And other serious health issues.

To confirm the hypothesis that concurrent menopause hormone therapy postmenopausal increases the effectiveness of tirzepetides for weight loss in women, researchers studied a real world. Electronic medical records Among the 120 postmenopausal women over an average period of 18 months. The study consisted of two colleagues: 40 women using menopause hormone therapy using tirzepatides and alone with 80 women alone.

The results showed Tirzepatide plus menopause hormone therapy (17%) than those using Tirzepetides (14%) alone, showing percentage of total body weight loss for women using menopause hormone therapy (17%). In addition, a high percent of the menopause hormone therapy users (45%) also received at least 20% total body Decrease in loadMenopause hormone therapy compared to 18% of non-uses.

Maria Daniella Hartado Andrade, MD, PhD, MD, PhD, MD, PhD, MD, PhD, MD, Assistant Professor and Advisor of Endocrinology for Assistant Professor and Advisor of Endocrinology for PhD, said, “Information obtained through this new study is the risk related to a postmanopose and object To reduce more effective and individual weight management provides significant insights to develop intervention, “said the division of endocrinology and assistant professor, MD, PhD of the division of endocrinology in the Mayo Clinic.

“This study underlines the immediate need for further research to understand in a better way that obesity drugs and menopause hormone therapy works together. Achieving this knowledge can greatly improve the health and well -being of millions of people. postmenopausal womenIt also indicates the need for better strategies to make these treatments more accessible and is available to those who need them. ,